secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0000950170-25-051576
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025
-------------------------------------------------------------------------------

- Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.
- Current CMO Jean-Marie Cuillerot departs on April 9, 2025.
- Dr. Mirza will lead Phase 2b trial of ACR-368 for endometrial cancer and Phase 1 trial of ACR-2316.
- He previously served as chief oncologist at Copenhagen University Hospital and medical director of NSGO CTU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/0000950170-25-051576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/acrv-20250407.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-051576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer